https://www.fiercebiotech.com/biotech/first-gen-mrna-flu-vaccines-wont-win-sanofi-execs-admit-the...
Developing thermostable or lyophilized mRNA vaccines （开发热稳定或者可以冻干的mRNA疫苗剂型）Screening n...
While current influenza vaccines are effective, they still have limitations, including narrow specificity for certain serological variants, which may result in a mismatch between vaccine antigens and circulating strains. Additionally, the rapid variability of the virus poses challenge...
The 8 worst technology failures of 2024Antonio Regalado Deep Dive Biotechnology and health The risk of a bird flu pandemic is rising Human cases in the US are on the rise and the virus is turning up in cows and dairy products. Luckily, we have some vaccines ready to go if needed. ...
Moderna already has a bird flu vaccine in very early-stage testing that uses the same mRNA technology that allowed rapid development and rollout of vaccines to protect against COVID-19. The new funds from the U.S. Department of Health and Human Services include continued dev...
Most clinical applications of mRNA to date have focused on vaccines for infectious disease and cancer for which low doses, low protein expression and local delivery can be effective because of the inherent immunostimulatory properties of some mRNA species and formulations. In addition, work on mRNA...
“The updated mRNA vaccines are manufactured using a similar process as previous formulations,” the FDA stated in the announcement. “In studies that have been recently conducted, the extent of neutralization observed by the updated vaccines against currently circulating viral variants causing COVID-19...
The authors further commented that “consensus is also lacking in the medical community regarding concerns that mRNA vaccines might cause more harm than initially forecasted.” From Los Angeles Times Federal officials also are exploring mRNA bird flu vaccines, which could be made very quickly, as th...
Biotech giant Moderna is using what some experts have called “21st-century science” to create three new vaccines to protect against the seasonal flu, HIV and Nipah virus, respectively, the company announced on Monday.
Influenza viruses cause substantial morbidity and mortality every year despite seasonal vaccination. mRNA-based vaccines have the potential to elicit more protective immune responses, but for maximal breadth and durability, it is desirable to deliver bot